Galapagos Shares Outstanding 2013-2021 | GLPG

Galapagos shares outstanding from 2013 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Galapagos Annual Shares Outstanding
(Millions of Shares)
2020 65
2019 60
2018 52
2017 49
2016 47
2015 36
2014 30
2013 29
2012 27
Galapagos Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 66
2021-03-31 67
2020-12-31 65
2020-09-30 66
2020-06-30 65
2020-03-31 65
2019-12-31 60
2019-09-30 60
2019-06-30 55
2019-03-31 55
2018-12-31 52
2018-09-30 53
2018-06-30 52
2018-03-31 51
2017-09-30
2017-03-31 48
2016-03-31 45
2015-12-31 36
2015-09-30 38
2015-06-30 32
2015-03-31 30
2014-12-31
2014-06-30
2013-12-31
2012-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.502B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29